期刊文献+

miR-140通过下调Pin1抑制乳腺癌BT549细胞上皮细胞-间充质转化

原文传递
导出
摘要 目的 用miR-140模拟物转染三阴型乳腺癌BT549细胞,检测Pin1在乳腺癌细胞系BT549中的表达情况,研究在BT549细胞中miR-140如何通过Pin1发挥对上皮细胞-间充质转化(EMT)的抑制作用。方法 用miR-140模拟物(miR-140模拟物组)、miR-140阴性对照(阴性对照组)转染BT549细胞,同时设置未处理组为空白对照组。利用实时PCR法检测不同组BT549细胞中的Pin1 mRNA表达水平;利用Western Blot检测E-钙黏蛋白及Pin1蛋白的表达水平;利用划痕试验研究转染miR-140对BT549侵袭能力的影响。结果 划痕后24 h,miR-140模拟物组、阴性对照组和空白对照组划痕宽度相对0 h变化的比例分别为23.4%、41.4%和53.1%。与阴性对照组和空白对照组相比,miR-140模拟物组BT549细胞迁移能力明显降低(χ~2=5.550,P〈0.05;χ~2=6.995,P〈0.05)。miR-140模拟物组、阴性对照组和空白对照组Pin1 mRNA表达水平分别为(0.55±0.02)、(0.89±0.06)和(1.05±0.06)。miR-140模拟物组Pin1 mRNA表达水平显著低于阴性对照组和空白对照组(t=8.823,P〈0.05;t=11.480,P〈0.05)。miR-140模拟物组、阴性对照组和空白对照组E-钙黏蛋白表达水平分别为(0.98±0.11)、(0.68±0.07)和(0.38±0.04)。miR-140模拟物组E-钙黏蛋白表达水平显著高于阴性对照组和空白对照组(t=7.990,P〈0.05;t=21.348,P〈0.05)。miR-140模拟物组、阴性对照组和空白对照组Pin1蛋白表达水平分别为(0.57±0.12)、(0.78±0.08)和(1.08±0.21)。miR-140模拟物组Pin1蛋白表达水平显著低于阴性对照组和空白对照组(t=8.921,P〈0.05;t=18.657,P〈0.05)。结论 miR-140可以抑制Pin1 mRNA转录,进而降低Pin1蛋白的表达水平,抑制EMT的发生。
出处 《中国妇幼保健》 CAS 2016年第5期1055-1057,共3页 Maternal and Child Health Care of China
  • 相关文献

参考文献5

二级参考文献60

  • 1Perou CM, Sodie T, Eisen MB, et al. Molecular portraits of human breast turnouts [ J]. Nature,2000,406 (6797) :747 - 752.
  • 2Sorlie T, Perou CM ,Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical impli- cations [ J ]. Proceedings NAS USA, 2001,98 ( 19 ) : 10869 - 10874,.
  • 3Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets [ J ]. Proceedings of the National Academy of Sciences of USA, 2003,100(14) :8418 - 8423.
  • 4Hennessy BT, Gonzalez - Angulo AM, Stemke - Hale K, et al. Characterization of a naturally occurring breast cancer subset en- riched in epithelial - to - mesenehymal transition and stem cell characteristics[J]. Cancer Res, 2009,69(10) :4116 -4124.
  • 5Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline rec- ommendations for human epidermal growth factor receptor 2 testing in breast cancer[J]. J Clin Oncol,2007,25( 1 ) :118 -145.
  • 6Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estro- gen receptor( ER ) - negative, progesterone receptor ( PR ) - nega- tive, and HER2 - negative invasive breast cancer, the so - called triple - negative phenotype: a population - based study from the California Cancer Registry [ J ]. Cancer, 2007,109 ( 9 ) : 1721 - 1728.
  • 7Christos Vaklavas, Andres Forero- tortes. How do I treat " triple - negative" disease [ J ]. Current Treat Options in Oncal, 2011,12 : 369 -388.
  • 8Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of pri- mary breast tumor improves survival of patients with metastatic breast cancer at diagnosis [ J ]. J Clin 0ncol,2006,24 ( 18 ) : 2743 - 2749.
  • 9Liedtke C, Masouni C, Hess KR, et al. Response to neoadjuvant therapy and long - term survival in patients with triple - negative breast cancer[ J ]. J Clin Oncol,2008,26 ( 8 ) : 1275 - 1281.
  • 10Creighton C J, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor - initi- ating features [ J ]. Proceedings of the National Academy of Sci USA ,2009,106 (33) : 13820 - 13825.

共引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部